Achieve Life Sciences (ACHV) EBITDA Margin (2010 - 2015)

Achieve Life Sciences (ACHV) posted EBITDA Margin of 6.51% for Q4 2015, down 98.21% on a QoQ basis from 363.15% in Q4 2012.

Achieve Life Sciences (ACHV) EBITDA Margin (2010 - 2015) Analysis & Trends

Achieve Life Sciences' EBITDA Margin history runs 4 years deep, the most recent figure standing at 6.51% for Q4 2015.

Quarterly EBITDA Margin changed N/A year-over-year to 6.51% in Q4 2015, while the trailing twelve-month figure through Dec 2015 was 276.11% (changed N/A YoY) and the FY2015 annual result came in at 2.16%, changed N/A from the prior year.
EBITDA Margin was 6.51% for Q4 2015 at Achieve Life Sciences, down from 363.15% in the prior quarter.
Across five years, EBITDA Margin topped out at 363.15% in Q4 2012 and bottomed at 7012.62% in Q4 2011.
A 3-year average of 723.6% and a median of 126.18% in 2012 frame the typical range for EBITDA Margin.
Annual changes were most pronounced in 2011 — EBITDA Margin tumbled 689266 bps — and 2012, when it jumped 737577 bps.
Achieve Life Sciences' EBITDA Margin stood at 7012.62% in 2011, then jumped by 105 bps to 363.15% in 2012, then slumped by 98 bps to 6.51% in 2015.
Business Quant data shows ACHV's EBITDA Margin at 6.51% in Q4 2015, 363.15% in Q4 2012, and 126.18% in Q3 2012.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Achieve Life Sciences	2.54 Mn	2.54 Mn	-	-

Download Data